ライフサイエンスコーパス: vitamin K epoxide

1 lyzes the conversion of reduced vitamin K to vitamin K epoxide and the concomitant conversion of glut

2 ants resulted in wild type VKOR reduction of vitamin K epoxide; however, the C43A and C51A mutants on

3 reductase complex subunit 1 (VKORC1) reduces vitamin K epoxide in the vitamin K cycle for post-transl

4 ion of the vitamin K-dependent proteins, and vitamin K epoxide is a by-product of this reaction.

5 The vitamin K epoxide (KO) product is recycled by two reacti

6 carboxylated reporter when fed vitamin K or vitamin K epoxide (KO).

7 Vitamin K epoxide (or oxido) reductase (VKOR) is the tar

8 arfarin and other 4-hydroxycoumarins inhibit vitamin K epoxide reductase (VKOR) by depleting reduced

9 Vitamin K epoxide reductase (VKOR) catalyzes the convers

10 oralis, and revealed the essential role of a vitamin K epoxide reductase (VKOR) gene in pilus assembl

11 Vitamin K epoxide reductase (VKOR) generates vitamin K h

12 isms in the cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR) genes have been shown

13 Vitamin K epoxide reductase (VKOR) is an essential enzym

14 Vitamin K epoxide reductase (VKOR) is essential for the

15 Vitamin K epoxide reductase (VKOR) is the target of warf

16 Subsequently, vitamin K epoxide reductase (VKOR) is thought to convert

17 The warfarin-sensitive enzyme vitamin K epoxide reductase (VKOR) of the cycle reduces

18 The intramembrane vitamin K epoxide reductase (VKOR) supports blood coagul

19 Vitamin K epoxide reductase (VKOR) sustains blood coagul

20 Despite its importance, warfarin's target, vitamin K epoxide reductase (VKOR), has resisted purific

21 agulation in humans requires the activity of vitamin K epoxide reductase (VKOR), the target of the an

22 K is in excess in both the untransfected and vitamin K epoxide reductase (VKOR)-transfected cells, th

23 ts quiescin-sulfhydryl oxidase 1 (QSOX1) and vitamin K epoxide reductase (VKOR).

24 Warfarin-resistant vitamin K epoxide reductase (VKOR-Y139F) supported carbo

25 Using the mammalian membrane protein vitamin K epoxide reductase (VKORc1) as a reporter, we d

26 rphisms in the cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase (VKORC1) genes.

27 d of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to diff

28 logous to the catalytic subunit of mammalian vitamin K epoxide reductase (VKORC1, EC 1.1.4.1) that is

29 n dosing is correlated with polymorphisms in vitamin K epoxide reductase complex 1 (VKORC1) and the c

30 Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affec

31 Vitamin K epoxide reductase complex subunit 1 (VKORC1) r

32 on its interaction with a splice variant of vitamin K epoxide reductase complex subunit 1 (VKORC1),

33 mented but uncharacterized splice variant of vitamin K epoxide reductase complex subunit 1 (VKORC1),

34 ctions of vIL-6 with the ER membrane protein vitamin K epoxide reductase complex subunit 1 variant 2

35 eviously uncharacterized ER membrane protein vitamin K epoxide reductase complex subunit 1 variant 2

36 ociates with a novel membrane protein termed vitamin K epoxide reductase complex subunit 1 variant 2

37 largely uncharacterized ER-resident protein vitamin K epoxide reductase complex subunit 1 variant 2

38 ide polymorphisms in cytochrome P450 2C9 and vitamin K epoxide reductase have been shown to make sign

39 on (Ci-Gla1, gamma-glutamyl carboxylase, and vitamin K epoxide reductase) or spatiotemporal regulatio

40 mplicate the bacterial homolog of the enzyme vitamin K epoxide reductase, a protein required for bloo

41 macromolecular interactions by inhibition of vitamin K epoxide reductase, cellular responses includin

42 orthologs of gamma-glutamyl carboxylase and vitamin K epoxide reductase.

43 oexpressing the recently identified gene for vitamin K epoxide reductase.

44 Vitamin-K epoxide reductase is encoded by the VKORC1 gen

45 We show that in vivo VKORC1L1 reduces vitamin K epoxide to support vitamin K-dependent carboxy

46 VKOR) sustains blood coagulation by reducing vitamin K epoxide to the hydroquinone, an essential cofa

47 tif are essential for both the conversion of vitamin K epoxide to vitamin K and the conversion of vit

48 is that VKOR catalyzes both the reduction of vitamin K epoxide to vitamin K and the conversion of vit

49 eptide can accomplish both the conversion of vitamin K epoxide to vitamin K and vitamin K to reduced